Vanguard reports 0 shares of Bio‑Rad in 13G/A
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed an amended Schedule 13G reporting that it currently beneficially owns 0 shares (0%) of Bio-Rad Laboratories Inc. The filing explains that on January 12, 2026 Vanguard completed an internal realignment and began reporting certain subsidiaries' holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did The Vanguard Group report for BIO in this Schedule 13G/A?
Why did Vanguard file an amendment to its 13G for Bio-Rad (BIO)?
Who signed the Schedule 13G/A amendment for BIO?
Does the filing indicate any third party holds more than 5% of BIO?
AI-generated analysis. How Rhea-AI works. Not financial advice.